Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682170 | 0.90 | KDM4E (0.45) | GPR119KDM4EPKMNAMPTBRD4 | |
| SCHEMBL4700022 | 0.87 | BRD4 (0.44) | KDM4EBRD4LMNAALDH1A1 | |
| SCHEMBL7667690 | 0.83 | NAMPT (0.52) | GPR119KDM4EPKMNAMPTLMNA | |
| SCHEMBL4682167 | 0.83 | NAMPT (0.44) | GPR119KDM4EPKMNAMPTLMNA | |
| SCHEMBL7673219 | 0.82 | NAMPT (0.53) | GPR119KDM4EPKMNAMPTLMNA | |
| SCHEMBL8333919 | 0.81 | GPR119 (0.54) | GPR119KDM4EPKMNAMPTPTPN2 | |
| SCHEMBL7670250 | 0.81 | NAMPT (0.54) | GPR119KDM4EPKMNAMPTLMNA | |
| SCHEMBL6608352 | 0.80 | NAMPT (0.51) | GPR119KDM4EPKMNAMPTLMNA | |
| SCHEMBL7667732 | 0.79 | NAMPT (0.48) | GPR119KDM4EPKMNAMPTLMNA | |
| SCHEMBL4675927 | 0.77 | GPR119 (0.50) | GPR119KDM4EPKMNAMPTSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | GPR119 7/4885KDM4E 1817/4885PKM 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.